Cencora makes the last mile matter

Consider the green plastic tote. It has none of the romance of a laboratory, none of the authority of a white coat. It rattles along a conveyor, carrying something that somebody, somewhere, needs. A pharmaceutical breakthrough still has to survive this part: the purchase order, the warehouse, the journey to a dispensing counter. Cencora has made an enormous business out of attending to what happens after the breakthrough.

Its customers include pharmaceutical manufacturers, independent pharmacies, hospital systems and physician practices. Animal health belongs here too. A biotech developing a treatment and a veterinarian replenishing supplies have different needs, but both depend on a chain of transactions that must work before care can happen.

Eighty-two cents on a hundred dollars

Cencora buys and distributes pharmaceuticals, then adds services around their movement and use. It earns wholesale margins and fees for work such as logistics, consulting and patient support. Those immense sales figures mostly reflect the value of the medicines passing through the business. In fiscal 2025, GAAP operating income amounted to about 82 cents per $100 of revenue. Adjusted operating margin, excluding specified items, was 1.31%.

That helps explain the obsession with dependable operations. A distributor needs volume, purchasing relationships, working capital and delivery discipline. McKesson and Cardinal Health compete for much of the same U.S. business. Cencora’s pitch combines that basic distribution engine with services reaching backward into drug development and forward into the practice. Customers can buy help with the surrounding complications as well as the shipment.

The company itself arrived by combination. AmeriSource and Bergen Brunswig merged in August 2001. The acquisition of most Alliance Healthcare businesses in 2021 enlarged its international operations. In August 2023, AmerisourceBergen became Cencora. The shorter name arrived after the business had already spread well beyond an American wholesaler’s original brief.

The box that took two years

For an independent pharmacist, the useful entry point might be Good Neighbor Pharmacy, which provides business and branding support. A manufacturer might need regulatory advice from PharmaLex, help with commercialization, or patient access services. World Courier handles specialized transportation, where maintaining a temperature can matter as much as meeting a delivery time.

One World Courier story makes the service business unusually tangible. In a 2017 video, then-president Sam Herbert recalled a European customer wanting to move pharmaceutical ingredients to the United States. The customer wanted lower cost without lower quality. World Courier spent two years designing the packaging solution that became Cocoon.

“We want it to be cheaper, but we don’t want any less quality.”A customer request, recalled by World Courier’s Sam Herbert, 2017

Today, Cocoon offers reusable passive containers in different sizes and temperature configurations, with location monitoring. The useful lesson is specific: a customer’s constraint can become a product specification. Before adding another service, identify the trade-off that keeps making customers wince. Then spend the engineering time to change it.

Buying a place beside the doctor

The more expensive version of that idea is to buy the infrastructure around care. In January 2025, Cencora acquired approximately 85% of Retina Consultants of America. Its cash outlay at closing was $4.4 billion, including debt repayment, capitalization and transaction expenses. Physicians and management retained a minority interest.

In February 2026, it acquired the majority of the OneOncology interests it did not already own for approximately $4.6 billion in cash consideration, financed with new debt. These management services platforms support practices with the business of operating. For Cencora, they deepen relationships with providers who use specialty medicines.

The direction continued on October 21, 2026, with an agreement to acquire American Oncology Network. The announced enterprise value was $2.4 billion, including up to $100 million of contingent value rights. AON had more than 350 oncology providers across 21 states. This is a signed deal awaiting approvals and other conditions, rather than another completed acquisition.

For a practice considering such a partner, the decision is practical: which administrative problems will the platform actually take over, and what remains the physician’s responsibility? For a manufacturer, the questions shift to market access, transport requirements and launch support. Cencora’s breadth gives it several ways into a customer relationship. It also makes the buying decision more demanding: the customer needs to choose a defined service and understand its terms.

The physical network still needs money. Cencora has announced $1 billion of U.S. distribution investment through 2030, including a second national distribution center in Ohio and added cold storage capacity. Practice services do not remove the need for warehouses. They give those warehouses more relationships to serve.

The expensive part of being wrong

Buying expertise does not guarantee demand. PharmaLex suffered weakening demand for specialized life sciences services. Cencora revised its long-range forecast and recorded goodwill impairments of $418 million in fiscal 2024 and $723.9 million in fiscal 2025. By September 2025, that reporting unit’s goodwill was fully impaired. That does not mean its services ceased to exist; it means the acquisition’s accounting expectations had to come down.

There are harder failures in the record. A subsidiary pleaded guilty in 2017 to distributing misbranded drugs; related criminal and civil resolutions totaled $885 million. Separately, the 2022 national distributor opioid settlement assigned AmerisourceBergen contributions of up to approximately $6.1 billion over 18 years. The distributors disputed the allegations. Moving medicines carries obligations about what moves, how it is handled and which orders deserve scrutiny.

Cencora describes its culture around a shared responsibility to create healthier futures, with career development, wellbeing and collaboration among its stated priorities. In a business that passes work between specialists, that ambition has an operational test: does the next person receive the right information, in time to act?

The model depends on compliance, customer retention and enough demand to justify expensive capacity. Better distribution cannot manufacture a missing drug. The practical lesson is to solve the obstacle between a product and its user, then measure whether the solution earns its keep. For Cencora, the final test is waiting at the counter.